Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Processa Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2009-01-01

Employees: 13

Market Cap: -

Website: http://www.processapharmaceuticals.com

Introduction: Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.

Clinical Trials

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer
TNBC - Triple-Negative Breast Cancer
HER2-negative Breast Cancer

Interventions: Drug: PCS6422 and capecitabine
Drug: Capecitabine

First Posted Date: 2024-08-23

Last Posted Date: 2025-06-19

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT06568692

Locations: 🇺🇸
Northwest Cancer Center, Dyer, Indiana, United States
🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 10 locations

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Drug: PCS12852
Drug: Placebo

First Posted Date: 2022-03-08

Last Posted Date: 2023-07-21

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT05270460

Locations: 🇺🇸
Torrance Clinical Research Institute, Inc., Lomita, California, United States
🇺🇸
TriWest Research Associates, San Diego, California, United States
🇺🇸
APF Research, LLC, Miami, Florida, United States

and more 6 locations

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

Phase 1

Completed

Conditions: Advanced Cancer
Refractory Cancer
Tumor Gastric

Interventions: Drug: PCS6422 and capecitabine

First Posted Date: 2021-04-27

Last Posted Date: 2024-10-10

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT04861987

Locations: 🇺🇸
Processa Clinical Site, Fairfax, Virginia, United States

A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Phase 2

Terminated

Conditions: Necrobiosis Lipoidica

Interventions: Drug: PCS499
Other: placebo

First Posted Date: 2021-03-16

Last Posted Date: 2023-08-03

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT04800562

Locations: 🇺🇸
Processa Clinical Site, Milwaukee, Wisconsin, United States

Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Trental
Drug: PCS499

First Posted Date: 2019-02-11

Last Posted Date: 2019-02-12

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT03836222

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

Phase 2

Completed

Conditions: Necrobiosis Lipoidica

Interventions: Drug: PCS499

First Posted Date: 2018-10-09

Last Posted Date: 2022-10-03

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT03698864

Locations: 🇺🇸
Processa Investigational Site, Pittsburgh, Pennsylvania, United States

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: RX-3117

First Posted Date: 2017-06-16

Last Posted Date: 2023-12-06

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT03189914

Locations: 🇺🇸
Rexahn Site, Milwaukee, Wisconsin, United States

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

Phase 1

Completed

Conditions: Solid Tumor
Metastatic Bladder Cancer

Interventions: Drug: RX-3117

First Posted Date: 2014-01-08

Last Posted Date: 2023-12-06

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT02030067

Locations: 🇺🇸
Rexahn Site, Fairfax, Virginia, United States

Open Label Extension Study of HT-100 in Patients With DMD

Phase 2

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: HT-100

First Posted Date: 2013-11-07

Last Posted Date: 2020-09-03

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01978366

Locations: 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸
Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 2 locations

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

Phase 1

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: HT-100

First Posted Date: 2013-05-07

Last Posted Date: 2020-09-03

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01847573

Locations: 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸
Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 2 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy